PEPTIDE CORTEXThe library
← The library

AOD-9604

researchMetabolic/Weight
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
In the shop · assay ↗
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight
MechanismSynthetic C-terminal fragment of hGH (residues 176-191); stimulates lipolysis and inhibits lipogenesis without binding the GH receptor
EffectsTargets fat metabolism without raising IGF-1 or affecting blood sugar in trials to date
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trialPhase 2b, oral (Metabolic Pharmaceuticals, reported 2004)
RouteOral
FrequencyOnce daily, 12 weeks
StartingFixed arms; no escalation
EscalationNone
TargetArms: 1, 5, 10, 20 or 30 mg. 1 mg did best: -2.8 kg vs -0.8 kg on placebo; higher doses were not better.

Company press only; no peer-reviewed efficacy paper located, and sources disagree on the trial arms. Development for obesity was halted. The community subcutaneous figure has no human-trial basis and is deliberately not shown.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyOnce daily, preferably in the morning on an empty stomach
Starting300 mcg SC once daily, weeks 1-4
Escalation500 mcg once daily, weeks 5-12
Target300-500 mcg/day SC
Cycle12 weeks (guides quote 8 to 20)

No published human trial ever tested AOD-9604 by injection; the only human trial was oral (1 mg/day was the best arm) and development for obesity was halted. The guide calls this an "anecdotal community standard".

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — Six Phase I/II trials showed a clean safety profile in ~900 participants, but the Phase IIb weight-loss endpoint was not met and development stopped in 2007.